Research & Treatment News
February 8, 2010
Upon first glance, the Valentine's Day tradition of gifting chocolates may seem counterintuitive for someone with Hepatitis C. Though, research boasts two reasons why the right kind of chocolate will show your sweetheart that you care about his or hers liver health.
Continue reading "Celebrating Valentine's Day: A Sweet Treat for Hepatitis C"
Posted by Editors at 12:26 PM
February 4, 2010
Conatus Pharmaceuticals is optimistic that their developmental drug, CTS-1027, will give people with Hepatitis C a greater chance for beating the virus. In a Phase II Hepatitis C trial for previous non-responders, CTS-1027 is being paired with pegylated interferon and ribavirin.
Continue reading "Hepatitis C Triple Therapy Trial Begins with CTS-1027"
Posted by Editors at 4:19 PM
February 2, 2010
February is American Heart Month. Since Hepatitis C has been proven to be a risk factor for coronary artery disease, the usual ways to reduce heart disease risk is insufficient for those with the virus. However, there are five strategies specifically for Hepatitis C that can reduce the likelihood of impending cardiac problems.
Continue reading "Hepatitis C Is a Risk Factor for Heart Disease"
Posted by Editors at 4:47 PM
January 27, 2010
By strategically interspersing liver cells and other specialized cells on growth plates, researchers have figured out how to grow Hepatitis C outside of the body - a critical tool to develop and test new Hepatitis C treatments.
Continue reading "Ability to Study Hepatitis C Aided by New Model"
Posted by Editors at 10:23 AM
Slowing down efforts to prevent or cure Hepatitis C, this virus has an uncanny ability to mutate and become resistant to new drugs. By identifying compounds that interfere with Hepatitis C's replication process, scientists at Stanford University have uncovered a potentially new approach for suppressing Hepatitis C that does not appear to be vulnerable to drug resistance.
Continue reading "Compounds Found That Halt Hepatitis C Replication"
Posted by Editors at 10:18 AM
January 26, 2010
An isomer of PSI -7851 (a polymerase inhibitor that has already demonstrated encouraging clinical results for Hepatitis C), Pharmasset believes that PSI-7977 would be more potent and better suited for manufacturing. Hence, Pharmasset has initiated a Phase 2a trial to test this substance on treatment naïve participants with Hepatitis C genotype 1.
Continue reading "Pharmasset Further Refines Its Hepatitis C Polymerase Inhibitor"
Posted by Editors at 3:13 PM